INCATE’s Post

Why does antibiotic resistance matter? One reason is that it creates even poorer outcomes for people already struggling with disease. It’s critical that we do everything we can to preserve the efficacy of antibiotics for those who need them. If you’re a healthcare provider looking for better ways to talk with patients about antibiotics, check out our website and videos: https://lnkd.in/eXsdHChH

Also known as Zithromax or Z-pak, azithromycin is a commonly prescribed antibiotic. Researchers are studying if this medication might be beneficial against cancer. Read on to learn more about the science behind the anticancer effects of azithromycin and how you may be able to use it to your benefit. https://lnkd.in/ddJucNf6

Challenges in the Management of Immune Checkpoint Inhibitor-Associated Hepatitis Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, but they can also cause immune-related adverse events (IRAE), including liver injury. This article explores the challenges of diagnosing and treating IRAE-associated hepatitis (IRH), including the risks and benefits of corticosteroids (CS) used to treat IRH. This is a great resource for anyone who wants to learn more about this important topic. Read the full article here: https://lnkd.in/eyVkfGmF #immunotherapy #cancer #liverdisease #gastroenterology #hepatology #hepatitis What are your thoughts on the challenges of managing IRAE-associated hepatitis?

Infections pose a significant threat to cancer patients. As we celebrate higher cancer survival rates, the shadow of antimicrobial resistance looms large, threatening to reverse these gains. The urgent need for new, effective antibiotics is clear; without them, the risk of dying from previously treatable infections will rise. The focus on high-cost cancer drugs may inadvertently shift attention and investment away from essential antibiotics, crucial for many cancer patients' survival. Balancing investment in cancer treatment with the development of new antibiotics is not just vital for patient care—it's an economic imperative. Ensuring we have robust defenses against infections is as crucial as advancing cancer care itself. https://lnkd.in/eWPCHwXY

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward #cancer #drugdevelopment #antibioticresistance https://hubs.la/Q02w8s8k0

Also known as Zithromax or Z-pak, azithromycin is a commonly prescribed antibiotic. Researchers are studying if this medication might be beneficial against cancer. Read on to learn more about the science behind the anticancer effects of azithromycin and how you may be able to use it to your benefit. https://lnkd.in/ddJucNf6

Feature - Trials to watch: Phase III BCG naïve non-muscle invasive bladder cancer There are several trials investigating new treatment options for BCG naïve patients given the ongoing BCG shortages. - https://lnkd.in/dH8egJRv #clinicaltrials #drugdevelopment

"Infections are the second-leading cause of death among cancer patients, and lead to one in five being hospitalised during treatment. Given that many cancer therapies weaken the immune system, making patients more susceptible to infections, this is to some extent to be expected. But increasingly clinicians see infections that are becoming drug-resistant — antibiotics once effective against them no longer work. Without new and effective antibiotics, this is only going to get worse, with more people surviving cancer only to die of an infection that was previously treatable." Global Antibiotic R&D Partnership (GARDP) World Anti-Microbial Resistance Congress  https://lnkd.in/e_uFVFUA

📣 Check out our Executive Director, Manica Balasegaram's insightful article on the growing threat of antibiotic resistance for cancer patients, in the Financial Times. 🌍💊 Don't miss this important read on the global challenge we're tackling everyday! 📰✨ #GARDP #AntibioticResistance #Healthcare #ReadNow

ASCP Daily Diagnosis 05/30 CST Patients with cancer receiving posaconazole for invasive fungal infections who had albumin levels at or below 3 g/dL were at increased risk for subtherapeutic levels of the medication. A higher initial dosing strategy and therapeutic drug monitoring for oncology patients with albumin ≥3 g/dL receiving posaconazole particularly for the treatment of invasive fungal infection could be considered. https://lnkd.in/gCVMmcMK